Lisdexamfetamine Dimesylate vs Nivolumab
Lisdexamfetamine Dimesylate vs Nivolumab: Overview
This comparison examines the pharmacological differences between Lisdexamfetamine Dimesylate and Nivolumab.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Pharmacokinetics
Half-life: Nivolumab — 27 days.
Chemical Properties
Type: Lisdexamfetamine Dimesylate — Small molecule; Nivolumab — Antibody.